{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:39:40Z","timestamp":1771616380373,"version":"3.50.1"},"reference-count":196,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Fundacao para a Ciencia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007440, UIDB\/04539\/2020, UIDP\/04539\/2020, LA\/P\/0058\/2020, 2023.02511.BD"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007440, UIDB\/04539\/2020, UIDP\/04539\/2020, LA\/P\/0058\/2020, 2023.02511.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression. It accounts for 10\u201320% of breast cancer cases, predominantly affecting younger women, and is associated with poor prognosis due to high recurrence rates and limited therapeutic options. Past treatment strategies relied solely on chemotherapy, but challenges such as metastatic potential and chemoresistance persisted. Recent advancements in neoadjuvant chemo-immunotherapy aim to address these limitations by combining chemotherapy with immune checkpoint inhibitors, with promising clinical trial results demonstrating improved response rates and survival outcomes. A central focus is placed on biomarker-based immune monitoring strategies, encompassing both tissue-based biomarkers\u2014such as programmed cell death ligand 1 (PD-L1) expression, microsatellite instability, tumor mutational burden, tumor-infiltrating lymphocytes (TILs), and gene expression signatures\u2014and blood-based biomarkers, including gene expression profiling, comprehensive immunophenotyping, and cytokine profiling. In addition, an emerging role of advanced imaging technologies, such as immuno-positron emission tomography (immuno-PET) and radiomics, could permit real-time immune monitoring. This review aims to provide a comprehensive overview of the current landscape of immune monitoring in TNBC, highlighting its challenges, predictive and prognostic value, and potential to guide clinical decision-making. By addressing key immune response biomarkers, technical limitations, and emerging technologies, we seek to outline strategies for optimizing treatment and enhancing personalized medicine approaches for TNBC patients. Future integration of innovative monitoring techniques holds promise for improving patient outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1654748","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:43:24Z","timestamp":1760507004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Munnawara Fatima","family":"Syeda","sequence":"first","affiliation":[]},{"given":"Rita Antunes","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Luana Madalena","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Ana Raquel","family":"Paiva","sequence":"additional","affiliation":[]},{"given":"No\u00e9mia","family":"Castelo Branco","sequence":"additional","affiliation":[]},{"given":"Tatiana","family":"Cunha Pereira","sequence":"additional","affiliation":[]},{"given":"Gabriela","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Rodrigues-Santos","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105640","article-title":"Prognostic impact of histological subtyping in triple-negative breast cancer","volume":"152","author":"Grosse","year":"2024","journal-title":"Hum Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1634\/theoncologist.2011-S1-61","article-title":"Molecular stratification of triple-negative breast cancers","volume":"16","author":"Perou","year":"2011","journal-title":"Oncologist (2011)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-201361","article-title":"Therapeutic targets in triple negative breast cancer","volume":"66","author":"O'Toole","year":"2013","journal-title":"J Clin Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23243","article-title":"The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004","volume":"112","author":"Brown","year":"2008","journal-title":"Cancer."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2559.2006.02467.x","article-title":"Metaplastic breast carcinomas are basal-like tumours","volume":"49","author":"Reis-Filho","year":"2006","journal-title":"Histopathology."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: A review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression\u00a0patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.01.002","article-title":"Prognosis of patients with triple-negative breast cancer: A population-based study from SEER database","volume":"23","author":"Zhou","year":"2023","journal-title":"Clin Breast Cancer."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04189-6","article-title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","volume":"149","author":"Mandapati","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.146","article-title":"Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens","volume":"67","author":"A'Hern","year":"1993","journal-title":"Br J Cancer."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over","volume":"18","author":"Paridaens","year":"2000","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0960327119888277","article-title":"A review on the cardioprotective mechanisms of metformin against doxorubicin","volume":"39","author":"Ajzashokouhi","year":"2020","journal-title":"Hum Exp Toxicol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9474823","article-title":"Mechanisms of anthracycline-enhanced reactive oxygen metabolism in tumor cells","volume":"2019","author":"Doroshow","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm277","article-title":"A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes","volume":"18","author":"Findlay","year":"2007","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.12.012","article-title":"Epirubicin: is it like doxorubicin in breast cancer? A clinical review","volume":"21","author":"Khasraw","year":"2012","journal-title":"Breast."},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157119","article-title":"Docetaxel resistance in breast cancer: current insights and future directions","volume":"26","author":"Postigo-Corrales","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1039\/b404358h","article-title":"Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatment","author":"Wheate","year":"2004","journal-title":"Chem Commun (Camb)."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/1568011053765994","article-title":"Multi-nuclear platinum drugs: a new paradigm in chemotherapy","volume":"5","author":"Wheate","year":"2005","journal-title":"Curr Med Chem Anticancer Agents."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S408","DOI":"10.1016\/j.annonc.2021.08.400","article-title":"119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after \u22654 years of follow-up: BrighTNess, a randomized phase III trial","volume":"32","author":"Loibl","year":"2021","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.critrevonc.2018.09.004","article-title":"Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies","volume":"131","author":"He","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.breast.2018.08.097","article-title":"Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy","volume":"42","author":"Wickberg","year":"2018","journal-title":"Breast."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7263","article-title":"Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the swedish breast cancer group 91 radiotherapy randomized clinical trial","volume":"35","author":"Sj\u00f6str\u00f6m","year":"2017","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial","volume":"16","author":"Kunkler","year":"2015","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2021881","DOI":"10.1001\/jamanetworkopen.2020.21881","article-title":"Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast cancer","volume":"3","author":"Zhai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.clbc.2016.05.011","article-title":"Radiotherapy in patients 70 years and older with triple-negative breast cancer","volume":"16","author":"Algan","year":"2016","journal-title":"Clin Breast Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114712","article-title":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic Malignancies","volume":"162","author":"Li","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-019-0154-9","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-016-0690-8","article-title":"Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer","volume":"18","author":"Liu","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02226-w","article-title":"Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer","volume":"128","author":"Beniey","year":"2023","journal-title":"Br J Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into CDK regulators: novel opportunities for cancer therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41597-022-01512-1","article-title":"Proteomic characterisation of triple negative breast cancer cells following CDK4\/6 inhibition","volume":"9","author":"Beykou","year":"2022","journal-title":"Sci Data."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215388","article-title":"The renaissance of CDK inhibitors in breast cancer therapy: an update on clinical trials and therapy resistance","volume":"14","author":"Abdelmalak","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B57","article-title":"EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number","volume":"51","author":"Sobande","year":"2015","journal-title":"Cesk Patol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.04.003","article-title":"EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells","volume":"147","author":"Talukdar","year":"2020","journal-title":"Adv Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.113396se","article-title":"The epidermal growth factor receptor\/Erb-B\/HER family in normal and Malignant breast biology","volume":"55","author":"Eccles","year":"2011","journal-title":"Int J Dev Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"J BioMed Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer","volume":"10","author":"Vikas","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity."},{"key":"B67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities","volume":"11","author":"Dai","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","article-title":"Current insight into the regulation of PD-L1 in cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes","volume":"26","author":"Ali","year":"2015","journal-title":"Ann Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer."},{"key":"B74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer."},{"key":"B76","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13045-021-01218-8","article-title":"The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2021-0407","article-title":"Very compelling\" Results for ADC in TNBC trial","volume":"12","year":"2022","journal-title":"Cancer Discov"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2020.07.001","article-title":"Updates in neoadjuvant therapy for triple negative breast cancer","volume":"21","author":"Tufano","year":"2021","journal-title":"Clin Breast Cancer."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1103-9","article-title":"Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study","volume":"124","author":"Huober","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-negative breast cancer: role of specific chemotherapy agents","volume":"16","author":"Isakoff","year":"2010","journal-title":"Cancer J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.03.026","article-title":"Management of triple negative breast cancer","volume":"19","author":"Oakman","year":"2010","journal-title":"Breast."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2007.n.012","article-title":"Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status","volume":"7","author":"Fern\u00e1ndez-Morales","year":"2007","journal-title":"Clin Breast Cancer."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-203","article-title":"Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer","volume":"7","author":"Keam","year":"2007","journal-title":"BMC Cancer."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2779","article-title":"Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL\u2013CALGB 150007\/150012, ACRIN 6657","volume":"30","author":"Esserman","year":"2012","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0333-1","article-title":"The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer","volume":"119","author":"Straver","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and\u00a0anthracycline-based chemotherapy versus placebo and chemotherapy in patients\u00a0with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v7.i5.387","article-title":"Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy","volume":"7","author":"Castaneda","year":"2016","journal-title":"World J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectab le, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.570623","article-title":"Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: A retrospective study of 440 patients","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"B118","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153997","article-title":"Tumor mutational burden in breast cancer: current evidence, challenges, and opportunities","volume":"15","author":"Barroso-Sousa","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B120","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1038\/s41586-019-1380-3","article-title":"Genomic characterization of metastatic breast cancers","volume":"572","author":"Bertucci","year":"2019","journal-title":"Nature."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.01.022","article-title":"Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability","volume":"35","author":"Prall","year":"2004","journal-title":"Hum Pathol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.648139","article-title":"Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives","volume":"11","author":"Yi","year":"2021","journal-title":"Front Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40001-024-01901-9","article-title":"Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer","volume":"29","author":"Jama","year":"2024","journal-title":"Eur J Med Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00156","article-title":"Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions","volume":"7","author":"Wein","year":"2017","journal-title":"Front Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/bcr3060","article-title":"A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies","volume":"13","author":"Muraro","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05371-0","article-title":"Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis","volume":"178","author":"Huang","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030953","article-title":"Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J Clin Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113037","article-title":"The value of tumor infiltrating lymphocytes (TIL) for predicting the response to neoadjuvant chemotherapy (NAC) in breast cancer according to the molecular subtypes","volume":"11","author":"Faur","year":"2023","journal-title":"Biomedicines."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051331","article-title":"Negative relationship between post-treatment stromal tumor-infiltrating lymphocyte (TIL) and survival in triple-negative breast cancer patients treated with dose-dense dose-intense neoAdjuvant chemotherapy","volume":"14","author":"Giacchetti","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy","volume":"40","author":"de Jong","year":"2022","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00973-w","article-title":"Effector memory cytotoxic CD3+\/CD8+\/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer","volume":"35","author":"Sun","year":"2022","journal-title":"Mod Pathol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"biomark Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J Exp Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197178","article-title":"Prognostic significance of interferon-\u03b3 and its signaling pathway in early breast cancer depends on the molecular subtypes","volume":"21","author":"Heimes","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834","article-title":"CANCER IMMUNOLOGY. The \"cancer immunogram","volume":"352","author":"Blank","year":"2016","journal-title":"Science."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670391","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1038\/s41467-024-47932-y","article-title":"Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122813","article-title":"Obesity-related inflammation reduces treatment sensitivity and promotes aggressiveness in luminal breast cancer modulating oxidative stress and mitochondria","volume":"12","author":"Morla-Barcelo","year":"2024","journal-title":"Biomedicines."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Badve","year":"2011","journal-title":"Mod Pathol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cyto.2003.10.004","article-title":"Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy","volume":"25","author":"Pusztai","year":"2004","journal-title":"Cytokine."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.03.10","article-title":"Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance","volume":"29","author":"Yu","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061788","article-title":"Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer","volume":"8","author":"Bender","year":"2013","journal-title":"PloS One"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19417","article-title":"Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget."},{"key":"B160","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2015.3234","article-title":"IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review)","volume":"48","author":"Long","year":"2016","journal-title":"Int J Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4827","article-title":"Differential regulation of T-cell growth by IL-2 and IL-15","volume":"108","author":"Cornish","year":"2006","journal-title":"Blood."},{"key":"B163","doi-asserted-by":"publisher","first-page":"59","DOI":"10.18388\/abp.2015_1153","article-title":"Interleukin 18 (IL-18) as a target for immune intervention","volume":"63","author":"Wawrocki","year":"2016","journal-title":"Acta Biochim Pol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5RU0714-360RR","article-title":"Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP","volume":"97","author":"Fabbi","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02527-0","article-title":"Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients","volume":"130","author":"Saldajeno","year":"2024","journal-title":"Br J Cancer."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba2609","article-title":"Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade","volume":"372","author":"Berry","year":"2021","journal-title":"Science"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat Rev Cancer."},{"key":"B168","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-024-00534-9","article-title":"A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking","volume":"8","author":"Ligero","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40425-016-0118-0","article-title":"Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials","volume":"4","author":"Kohrt","year":"2016","journal-title":"J Immunother Cancer."},{"key":"B170","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer."},{"key":"B171","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1038\/s41467-024-49051-0","article-title":"Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer","volume":"15","author":"Costa","year":"2024","journal-title":"Nat Commun"},{"key":"B172","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/s12885-023-11362-8","article-title":"The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer","volume":"23","author":"Divoux","year":"2023","journal-title":"BMC Cancer."},{"key":"B173","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"B175","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-01","article-title":"Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients with triple-negative breast cancer or HER2\u2013, BRCA-mutated breast cancer with molecular residual disease after de!nitive therapy","volume-title":"Clin Cancer Res","author":"Turner","year":"2025"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2015.16","article-title":"Single-cell genome sequencing: current state of the science","volume":"17","author":"Gawad","year":"2016","journal-title":"Nat Rev Genet"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/nm1764","article-title":"Stromal gene expression predicts clinical outcome in breast cancer","volume":"14","author":"Finak","year":"2008","journal-title":"Nat Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27648","article-title":"Targeting tumor-associated macrophages as a novel strategy against breast cancer","volume":"116","author":"Luo","year":"2006","journal-title":"J Clin Invest."},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0145-x","article-title":"B cell regulation of the anti-tumor response and role in carcinogenesis","volume":"4","author":"Schwartz","year":"2016","journal-title":"J Immunother Cancer."},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B184","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13059-015-0692-3","article-title":"Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells","volume":"16","author":"Kim","year":"2015","journal-title":"Genome Biol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"296fs29","DOI":"10.1126\/scitranslmed.aac8319","article-title":"Delineating cancer evolution with single-cell sequencing","volume":"7","author":"Navin","year":"2015","journal-title":"Sci Transl Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S388534","article-title":"Advances in single-cell sequencing technology and its applications in triple-negative breast cancer","volume":"14","author":"Li","year":"2022","journal-title":"Breast Cancer (Dove Med Press)."},{"key":"B187","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41523-021-00319-4","article-title":"Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer","volume":"7","author":"Bortolini Silveira","year":"2021","journal-title":"NPJ Breast Cancer."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De Rubis","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051671","article-title":"Circulating tumor cells in early and advanced breast cancer; biology and prognostic value","volume":"21","author":"Fabisiewicz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.21548","article-title":"Free circulating tumor DNA as a diagnostic marker for breast cancer","volume":"26","author":"Hashad","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184619","article-title":"Technical challenges for CTC implementation in breast cancer","volume":"13","author":"Ramos-Medina","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00134","article-title":"Circulating tumor cells in metastatic breast cancer: from genome instability to metastasis","volume":"7","author":"Ivanova","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating\u00a0tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"NPJ Breast Cancer."},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin Chem"},{"key":"B196","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1038\/s41598-020-71236-y","article-title":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","volume":"10","author":"Cavallone","year":"2020","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:43:26Z","timestamp":1760507006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":196,"alternative-id":["10.3389\/fimmu.2025.1654748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1654748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1654748"}}